Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A financing led by Atlas Venture, with participation from ...

The delivery of β 2-agonists in the ED setting by nebulizers or MDIs with holding chambers ( eg, AeroChamber, Volumatic, or InspirEase) is equally effective for improving pulmonary function and ...

Smoking is the most well-established cause of chronic airflow obstruction (CAO) but particulate air pollution and poverty have also been implicated. We regressed sex-specific prevalence of CAO from 41 ...